Nearly four months after the FDA failed to approve its lead drug candidate, Inspire Pharmaceuticals is still unsure about the drug's future.
Inspire officials said on Tuesday that a March 22 meeting with the FDA produced no firm conclusions about the future of diquafosol tetrasodium opthalmic solution, and the agency had requested additional information about the drug.
"Based on this meeting, we intend to provide the FDA with additional information to facilitate ongoing discussions related to diquafosol," Inspire Chief Executive Officer Christy Shaffer said in a written statement Tuesday. "We expect to provide the information to the FDA and continue our discussions with them over the next several months."
And their recent meeting with the FDA, how was that?
"We're really not in a very different place now than we were before," Inspire spokeswoman Mary Bennett says. "Unfortunately, this meeting really just didn't come to a conclusion."
More here at Yahoo Biz
Insiders' view: to quote the popular UK singer "The Streets" - dry your eyes, mate!
1 comment:
I wonder what they are going to do here. the 3rd time has to be the charm! Not sure what to make of it. What do you think?
Post a Comment